Jazz Pharmaceuticals JAZZ Impairment of long-lived assets
Impairment of long-lived assets at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:TangibleAssetImpairmentCharges.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's impairment of long-lived assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's impairment of long-lived assets?
- Jazz Pharmaceuticals (JAZZ) reported impairment of long-lived assets of $0 in Q4 2025.
- What does impairment of long-lived assets mean?
- A non-cash charge taken when an asset's value is determined to be lower than its recorded book value.
- How do you interpret impairment of long-lived assets?
- High impairment charges signal poor past investment decisions or a decline in the business environment.
- How does impairment of long-lived assets compare across companies?
- Occurs periodically across all industries, often during restructuring or economic downturns.